New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

Data ReadoutpositiveTREMFYAPositive

AI Analysis

Summary

TREMFYA (guselkumab) demonstrated consistent perianal fistula remission rates of up to 28% in prespecified Crohn's disease patient subgroups, including those with prior biologic exposure, supporting continued clinical development.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Prespecified subgroup analyses showed consistent perianal fistula remission rates up to 28% across key patient populations including those with prior biologic exposure

Importance:6/10

Sentiment:

0.70

Crohn's diseasefistula remissionsubgroup analysisbiologic therapyTREMFYA

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 12, 2026 8:05 PM

Read Original